Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as [203Pb]Pb-PSV359
Pb-PSV359 · 1 trial · 8 indications
Incidence and severity of treatment-related adverse events following a single administration of \[203Pb\]Pb-PSV359 is determined
Incidence and severity of treatment-related adverse events following a single and each repeated administration of \[212Pb\]Pb-PSV359 is determined
The recommended phase 2 dose as determined by cohort observations and review by the Safety Monitoring Committee
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | * Enrolled subjects are administered \[203Pb\]Pb-PSV359 (7mCi) for imaging FAP-expressing cancers. * Approximately Four cohorts of \[212Pb\]Pb-PSV359 dose levels will be explored for determining Recommended Phase 2 Dose (RP2D). Study subjects will be assigned to cohorts sequentially. |
| Dose Expansion | EXPERIMENTAL | * Enrolled subjects are administered \[203Pb\]Pb-PSV359 (7mCi) for imaging FAP-expressing cancers. * Enrolled subjects are administered \[212Pb\]Pb-PSV359 (RP2D determined previously) for treatment of FAP-expressing cancers |
| Name | Type | Description |
|---|---|---|
| [203Pb]Pb-PSV359 | DRUG | \[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging. |
| [212Pb]Pb-PSV359 | DRUG | \[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers. |
Inclusion Criteria: * Aged ≥ 18 years * Satisfactory organ function as determined by laboratory testing * Eastern Cooperative Oncology Group performance (ECOG) status of 0 to 1 * Life expectancy \> 3 months * Progressive disease despite standard therapy or for whom no standard therapy exists * Posi...
Pb-PSV359 is an investigational small molecule radiopharmaceutical being developed by Perspective Therapeutics, Inc. for pancreatic ductal adenocarcinoma and other solid tumors. It is designed to deliver targeted radiation to cancer cells and is currently in Phase 1 clinical development.
Pb-PSV359 targets fibroblast activation protein, or FAP, which is expressed in the tumor microenvironment of many solid tumors. By binding to FAP, the drug aims to deliver therapeutic radiation selectively to FAP-expressing cells.
Pb-PSV359 is being developed by Perspective Therapeutics, Inc., a biopharmaceutical company. The company's ticker symbol is CATX.
Pb-PSV359 is in Phase 1 clinical development. It is an investigational therapy and has not been approved by the FDA for any indication.
Pb-PSV359 is being evaluated in a Phase 1 clinical trial, NCT06710756, titled Lead-212 PSV359 Therapy for Patients With Solid Tumors. The trial is currently recruiting participants and has an estimated enrollment of 112 patients.
Yes, Pb-PSV359 is also known as [203Pb]Pb-PSV359. The bracketed notation indicates the isotope used in the compound. Both names refer to the same investigational radiopharmaceutical.